

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

NCT06398158

Status	RECRUITING
Sponsor	University of Texas Southwestern Medical Center
Enrollment	35 participants

Key Eligibility Criteria

Inclusion (4)

- Signed informed consent available prior to conduct of any study associated activities
- Men and women \geq 18 years of age
- Aquaporin-4 IgG positive people with neuromyelitis optica spectrum disorder treated with commercially available ravulizumab in a manner consistent with the approved indication
- Expanded Disability Status Scale score of \leq 7.0

Exclusion (6)

- Individuals who are intolerant to MRI
- Individuals previously exposed to eculizumab with treatment discontinuation due to lack of effective disease control (i.e., clinical relapse or demonstration of MRI advancement after 12 weeks of sustained treatment exposure)
- Unresolved meningococcal disease
- History of an active infection
- Existing participation in neuromyelitis optical spectrum disorder interventional clinical studies
- ... and 1 more (see full listing online)

Locations (1 total)

UT Southwestern Medical Center, Dallas, Texas, United States